KRAS and cancer: Previous genome-wide studies17, 20 to uncover KRAS synthetic lethality did not identify CDKN1A as a synthetic lethal gene in KRAS-mutant cancer, primarily because those screens were based on the loss-of-function interference rather than gain-of-function phenotypes.